Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
30/03/2026 14:47
March 30 (Reuters) - Aquestive Therapeutics Inc AQST.O: AQUESTIVE THERAPEUTICS ANNOUNCES COMPLETION OF TYPE A MEETING WITH FDA FOR ANAPHYLM™ (DIBUTEPINEPHRINE) SUBLINGUAL FILM AQUESTIVE THERAPEUTICS INC - REAFFIRMS GUIDANCE TO RESUBMIT ANAPHYLM NDA IN Q3 2026 AQUESTIVE THERAPEUTICS INC - RECEIVES CLARIFYING FEEDBACK FROM FDA ON PHARMACOKINETIC (PK) & HUMAN FACTOR (HF) STUDY DESIGNS AQUESTIVE THERAPEUTICS INC - CONTINUES TO ADVANCE REGULATORY SUBMISSIONS FOR ANAPHYLM IN CANADA AND THE EUROPEAN UNION Source text: ID:nGNX9NFVXy Further company coverage: AQST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million